Investigation of the Safety and Efficacy of Semaglutide s.c. in Combination With NNC0480-0389 in Participants With Type 2 Diabetes - a Dose Finding Study
Latest Information Update: 11 Apr 2024
At a glance
- Drugs NNC0480-0389 (Primary) ; Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 11 Apr 2024 This trial has been completed in Greece (End date:2023-03-23) according to European Clinical Trials Database record.
- 30 Mar 2023 Status changed from active, no longer recruiting to completed.
- 11 Nov 2022 Planned End Date changed from 30 Jan 2023 to 20 Mar 2023.